DividendJuly 29, 2026

Dividend Win Wednesday: Insiders Buy Energy at 16% Off While Semiconductors Trade 91% Down

Top 5 Pixie Picks

This Week's Setup

ConocoPhillips and Newmont hold the top two dividend ranks while insider buying persists across energy and materials.

KLA Corporation trades at a 90.7% drawdown with a 15.0% free cash flow yield, the widest discount on the screen, as semiconductor capital equipment marks its worst month since the 1987 crash.

Fear sits at 34, and the S&P 500 CAPE remains at 38.9, well above historical norms, while payout ratios across the top eight names average 40%, leaving plenty of cash for operations and capital allocation beyond the dividend.

Quick Scan

#	Ticker	One-line thesis
1	NEM	Gold miner at 32% drawdown with 7.5% FCF yield
2	COP	Energy insider adds while FCF covers payout 1.8×
3	KLAC	Semiconductor toolmaker at 91% off with 15% FCF yield
4	NVS	Swiss pharma near highs with 7.2% dividend growth
5	EOG	Independent oil producer with 28× interest coverage
6	GILD	HIV franchise with 5.7% FCF yield and insider adds
7	CI	Managed care at 11% drawdown with 10.5% FCF yield
8	BIIB	Multiple sclerosis leader with 10 insider buys, zero sells

The 8 Names

1. Newmont Corporation (NEM)

Dividend yield: 1.1% | Payout ratio: 15.7% | 52w drawdown: -32.3%

The 7.5% free cash flow yield at a 32% drawdown gives Newmont 4.8× payout cover, the most efficient dividend on the screen. Return on invested capital sits at 29.9%, and gross margins run at 53.2%, both multi-year highs for the gold sector as costs moderate and grades improve.

Revenue growth of 21.3% year-over-year is accelerating, but analysts assign an implied upside of 56.3% to a $142.82 target, signaling skepticism that production volumes will hold at current levels as legacy mines deplete.

Insider Peter Toth sold shares on July 6, marking the sixth consecutive month of net insider selling. Total insider activity over six months shows 18,394 net shares sold with zero buys.

2. ConocoPhillips (COP)

Dividend yield: 2.9% | Payout ratio: 51.3% | 52w drawdown: -16.0%

The 5.2% free cash flow yield covers the dividend 1.8×, and the company generated $19.8 billion in revenue last quarter while maintaining a 25.1% gross margin. Net debt to EBITDA sits at 0.73, below the 1.0 threshold that typically triggers capital allocation constraints in energy.

Silvina Vatnick bought shares on July 27 and July 10, adding to a position while the stock trades 16% below its 52-week high. The timing follows a 7.7% year-over-year revenue increase and an analyst target of $142.77, implying 25.1% upside.

Earnings are due August 6, with consensus expecting $2.89 per share on $19.8 billion in revenue. If realized prices for Brent or WTI crude fall below the $75 per barrel assumption embedded in that estimate, the shareholder yield of 3.6% becomes harder to sustain.

3. KLA Corporation (KLAC)

Dividend yield: 4.8% | Payout ratio: 29.6% | 52w drawdown: -90.7%

The 15.0% free cash flow yield at a 90.7% drawdown is the highest on the screen, and the company maintains a 60.9% gross margin alongside 66.5% return on invested capital. Net debt to EBITDA is 0.20, giving KLA ample flexibility to sustain the dividend and fund process control R&D.

Barron's reported that KLA is on pace for its worst month since 1987, and UBS cut its target to $215 from $240 while New Street lowered its target to $190 from $220. The analyst target of $1,855.14 implies 870.2% upside, a figure that reflects pre-crash expectations rather than current memory and logic capital equipment demand.

Bren Higgins bought shares on July 6 and July 2, and Mary Beth Wilkinson added on July 2, totaling three insider purchases as the stock trades below $200. Earnings come out later this week; consensus expects that wafer inspection tool orders will remain subdued as DRAM and NAND fabs defer expansions.

4. Novartis AG (NVS)

Dividend yield: 3.0% | Payout ratio: 64.7% | 52w drawdown: -6.3%

The 5.0% free cash flow yield supports a dividend that has grown at 7.2% annually over five years, and gross margins of 75.8% give Novartis pricing power in specialty pharma. Return on invested capital is 16.0%, and interest coverage stands at 15.3×, reflecting a fortress balance sheet.

Analysts assign a $153.87 target to a stock trading at $159.76, implying -3.7% downside. Barron's noted that the company cut earnings guidance, though the article argued the revision does not reflect the full franchise strength.

Net debt to EBITDA sits at 1.75, the highest ratio in the group. If biosimilar competition accelerates for Cosentyx or Entresto, the payout ratio of 64.7% leaves limited room to absorb revenue erosion without cutting the dividend.

5. EOG Resources, Inc. (EOG)

Dividend yield: 2.9% | Payout ratio: 43.6% | 52w drawdown: -7.6%

The 4.6% free cash flow yield covers the dividend 1.6×, and EOG maintains 28.1× interest coverage with net debt to EBITDA at 0.35. The company generated $8.0 billion in revenue last quarter with a 63.4% gross margin, the best in the independent oil sector as Permian basin efficiencies compound.

Michael Donaldson, Ann Janssen, and Ezra Yacob all sold shares on July 2, part of a pattern that shows 14,343 net shares sold over six months with zero insider buys. The selling coincides with a 7.6% drawdown and follows a quarter in which revenue declined 3.4% year-over-year.

Earnings are due August 4, with consensus expecting $4.99 per share. Goldman Sachs cut its target to $127 from $129 and maintains a neutral rating, signaling concern that oil prices will remain range-bound and limit the company's ability to grow free cash flow beyond current levels.

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.

6. Gilead Sciences, Inc. (GILD)

Dividend yield: 2.4% | Payout ratio: 47.9% | 52w drawdown: -14.3%

The 5.7% free cash flow yield at a 14.3% drawdown gives Gilead 2.3× payout cover, and the company maintains a 78.8% gross margin while generating 24.4% return on invested capital. Interest coverage sits at 10.6×, and net debt to EBITDA is 0.84, below the 1.5 threshold that typically triggers rating agency scrutiny.

Andrew Dickinson and Johanna Mercier both bought shares on July 16, and Daniel O'Day added on July 2, marking three insider purchases in a two-week window. The buying follows news that Atea Pharmaceuticals' hepatitis C drug matched Gilead's in a pivotal trial, raising competition risk for the company's HCV franchise.

Earnings are due August 4, with consensus expecting -$7.24 per share. That negative figure reflects Trodelvy impairment charges, not operating losses, but if oncology sales disappoint or HIV competition intensifies, the 47.9% payout ratio leaves limited cushion before capital allocation priorities shift.

7. The Cigna Group (CI)

Dividend yield: 2.1% | Payout ratio: 27.7% | 52w drawdown: -11.1%

The 10.5% free cash flow yield is the second-highest on the screen, and the payout ratio of 27.7% leaves $7.8 billion in annual free cash flow available for buybacks and M&A after dividends. Return on invested capital is 11.2%, and the company generated 11.7% revenue growth year-over-year as pharmacy benefit volumes increased.

The price-to-earnings ratio of 2.65 and earnings yield of 37.7% signal that investors expect either multiple compression from regulation or margin erosion in the PBM segment. Net debt to EBITDA sits at 1.72, the highest in the group outside of Novartis.

James Lee bought shares on July 24 as the stock trades at an 11.1% drawdown. Earnings are due July 30, with consensus expecting $7.60 per share on $70.2 billion in revenue. Zacks asked whether declining medical customers will affect second-quarter results, pointing to employer group losses in the first half of the year.

8. Biogen Inc. (BIIB)

Dividend yield: 0.0% | Payout ratio: 0.0% | 52w drawdown: -1.0%

Biogen does not pay a dividend, but it appears on the screen because of its 6.5% free cash flow yield and 10 insider buys over six months with zero sells. The company generated 7.0% return on invested capital and 75.7% gross margins, and it beat second-quarter expectations as the growth portfolio drove revenue higher.

Ten insiders bought a combined net total of three shares over six months, a pattern that signals confidence at negligible dollar amounts. The precision of the buying suggests restricted stock conversions or option exercises rather than open-market purchases, but the zero-sell component is the relevant signal.

Earnings are due July 29, with consensus expecting $2.33 per share on $2.6 billion in revenue. The company carries net debt to EBITDA of 0.64 and interest coverage of 6.8×, the lowest in the group, limiting flexibility to fund late-stage pipeline programs or return capital beyond buybacks.

What to Watch

July 29: Biogen earnings; consensus expects $2.33 per share on $2.6 billion in revenue. The growth portfolio drove second-quarter beats, so guidance for Alzheimer's and rare disease franchises will clarify whether the company can sustain 2.2% revenue growth.
July 30: Cigna earnings; consensus expects $7.60 per share on $70.2 billion in revenue. Declining medical customers are a known headwind, and any further deterioration in employer group enrollment could pressure the 27.7% payout ratio.
August 4: EOG Resources and Gilead earnings. EOG consensus is $4.99 per share; Gilead consensus is -$7.24 per share (impairment-driven). Oil price realizations and HCV competition are the two clearest catalysts.
August 6: ConocoPhillips earnings; consensus expects $2.89 per share on $19.8 billion in revenue. Silvina Vatnick's July 27 buy suggests internal confidence, but crude prices below $75 per barrel would undermine the 5.2% free cash flow yield.

Go Deeper

The dividend screener ranks companies by payout sustainability, free cash flow cover, and insider confidence.
Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Stock Pixie Pro

See the full dividend screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

Or start with the free Market Brief Digest

Where the market stands before the open, in plain language, every trading day. No account needed.

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.